EL7.AI
StocksMedium•15 October 2026•
4 min read

European panel recommends Rasonk approval after 60% reduction in pancreatic cancer death risk

Key Facts

1The company reported a 60% reduction in the risk of death compared with chemotherapy across all trial participants.
2Median overall survival in the primary analysis was 13.2 months with the drug versus 6.7 months with chemotherapy.
3The objective response rate was 30% with the drug versus 11% with chemotherapy.
4The rolling review shortened the drug's European assessment period to less than 150 days, according to the Spanish medicines agency.

Revolution Medicines announced on 15 October 2026 that its drug Rasonk had received a European recommendation for marketing authorisation to treat metastatic pancreatic cancer, after reporting a 60% reduction in the risk of death compared with chemotherapy. The company said in a statement that the European Medicines Agency's Committee for Medicinal Products for Human Use had adopted a positive opinion on the drug. The recommendation covers its use as monotherapy for adults with metastatic pancreatic adenocarcinoma. The recommended use is limited to patients who have received at least one prior systemic therapy. The recommendation marks a step in the European regulatory process for the drug, which has already received U.S. approval. The decision on marketing authorisation in the European Union remains with the European Commission, to which the committee's opinion will be referred.

The efficacy results were based on a pivotal trial that randomly assigned 500 patients to the drug or chemotherapy, according to the U.S. Food and Drug Administration. Patients were assigned in a 1:1 ratio, allowing treatment outcomes to be compared between the trial's two groups. The FDA reported that median overall survival in the primary analysis was 13.2 months among patients receiving the drug, compared with 6.7 months among those receiving standard chemotherapy. This measure represents the median overall survival time in each treatment group. In its statement, the company described the comparison as showing a "60% reduction in the risk of death compared with chemotherapy". The result covered all trial participants, according to the announcement, with chemotherapy serving as the comparator in the assessment of death risk.

Revolution Medicines' statement also reported results from a later, unplanned analysis, in which median overall survival with Rasonk was 12.4 months. In the comparator group, median survival with chemotherapy was 6.7 months in that analysis. The survival estimate for patients receiving the drug therefore differed between the primary and subsequent analyses, while the estimate for the chemotherapy group remained unchanged. Alongside the survival results, the trial recorded a difference in objective response rates between the two treatments, according to the FDA. The rate was 30% in the drug group, compared with 11% in the chemotherapy group, across all participants. The objective response figures relate to the pivotal trial comparing the drug with chemotherapy, while the company attributed the latest survival estimate to the subsequent analysis.

Rasonk contains the active ingredient daraxonrasib, which binds to the protein cyclophilin A, according to the drug's approved U.S. prescribing information. This binding forms a complex that blocks the activity of RAS proteins and inhibits signalling associated with cancer cell growth. For its approved U.S. use, the FDA set the recommended dose at 300 mg taken orally once daily. Treatment continues at this dose until disease progression or unacceptable toxicity, according to the U.S. prescribing information. On safety, U.S. warnings include the risk of gastrointestinal perforation in patients receiving the drug. They also include interstitial lung disease or pneumonitis among the warnings in the U.S. information for the drug whose trial showed the announced efficacy results.

The FDA approved Rasonk on 26 August 2026, before the announcement of the positive European opinion. When U.S. approval was announced, Reuters reported that Revolution Medicines had made the drug available in the United States at a price of $39,800 for a 30-day supply. The announced price concerned the drug's availability in the U.S. market, where it had received approval at the time. In its coverage that day, Reuters said the company's shares were little changed at $211.70 following the U.S. decision. Reuters described U.S. approval as widely expected in its coverage of the share-price movement. That market movement occurred on the day of U.S. approval in August, before the announcement of the European committee's recommendation for marketing authorisation in October.

In the European process, the Spanish Agency of Medicines and Medical Devices said the rolling review had shortened Rasonk's assessment period to less than 150 days. The agency attributed the reduction in assessment time to this approach to reviewing the drug as part of the consideration of its authorisation application. The committee's assessment concluded with the positive opinion announced by the company on 15 October 2026. The opinion recommends granting European marketing authorisation for the treatment of metastatic pancreatic cancer in the specified patient population. The next step is to refer the opinion to the European Commission, according to the Spanish agency. The Commission will decide on marketing authorisation, making that the next regulatory milestone following the committee's recommendation announced in October.

Open on chart